Valeant Pharmaceuticals International Inc. will expand its sales force and launch a direct-to-consumer advertising campaign to support the launch of Jublia (efinaconazole), a topical antifungal to treat onychomycosis, CEO Michael Pearson said during a conference call June 17.
Valeant Plans Sales Rep Increase, DTC Campaign For Jublia
Valeant has something to prove with the launch of Jublia, a topical treatment for toenail fungus, which it has held up as an example of its R&D strategy at work.